- IN₹373.62bn
- IN₹567.42bn
- IN₹147.56bn
- 54
- 20
- 33
- 25
Annual balance sheet for Biocon, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | — | — | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 18,551 | 32,233 | 29,645 | 37,260 | 25,738 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 18,622 | 22,370 | 27,805 | 40,114 | 72,591 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 53,250 | 76,004 | 83,823 | 123,340 | 151,792 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 70,980 | 79,641 | 93,643 | 101,226 | 119,778 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 144,438 | 185,223 | 203,940 | 520,428 | 560,707 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 40,080 | 42,101 | 38,280 | 85,107 | 153,588 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 77,380 | 108,954 | 119,615 | 341,759 | 362,870 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
ESOP Debt Guarantee | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 67,058 | 76,269 | 84,325 | 178,669 | 197,837 |
Total Liabilities & Shareholders' Equity | 144,438 | 185,223 | 203,940 | 520,428 | 560,707 |
Total Common Shares Outstanding |